Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03602014
Recruitment Status : Recruiting
First Posted : July 26, 2018
Last Update Posted : August 8, 2019
Sponsor:
Collaborator:
New York State Department of Health
Information provided by (Responsible Party):
Jill M. Wecht, Ed.D., James J. Peters Veterans Affairs Medical Center

Brief Summary:

The goal of this study is to determine the efficacy of the drug Droxidopa (Northera) in increasing blood pressure in subject with hypotension, low blood pressure, which is classified as blood pressure less than 110/70 in males and 100/70 in females. The first aim is to determine the proportion of subject with Spinal Cord Injury (SCI) who have a normotensive response to Droxidopa. The second is to determine the proportion of subject with SCI who express a hypertensive response to Droxidopa. A Normal blood pressure ranges from 111-139 in males and 101-139 in females and a hypertensive blood pressure is anything higher than 140 in males and females.

The study would take place in James J. Peters VA Medical Center (JJPVAMC) and The Icahn School of Medicine at Mount Sinai (ISMMS) in Manhattan, New York.


Condition or disease Intervention/treatment Phase
Hypotension, Orthostatic Hypotension Spinal Cord Injuries Drug: Northera Phase 4

Detailed Description:
Interruption of sympathetic cardiovascular autonomic regulation following spinal cord injury (SCI) is associated with significantly reduced plasma norepinephrine (NE) levels, hypotension and orthostatic hypotension (OH), particularly in individuals with high cord lesions. Although the incidence of hypotension is reported to be as high as 70% in persons with cervical lesions (i.e., tetraplegia), the vast majority of these individuals remains asymptomatic and, therefore, does not raise clinical concern, or prompt intervention. While it is appreciated that clinicians are faced with substantial challenges in managing blood pressure (BP) in persons with SCI, contrary to the prevailing belief, asymptomatic hypotension and OH are not benign conditions. Reports suggest that asymptomatic hypotensive individuals with SCI may have subclinical cognitive dysfunction affecting memory and attention processing and increased incidence of fatigue and depression compared to normotensive individuals with SCI. It must be appreciated that to date, there are no FDA approved pharmaceutical options proven to be safe and effective for treatment of hypotension and OH in the SCI population. Until 2014, midodrine hydrochloride was the only agent with FDA approval for treatment of symptomatic neurogenic OH (NOH). Midodrine, an alpha-agonist, is the most commonly prescribed agent used to treat symptomatic hypotension in the SCI population despite a lack of convincing evidence of safety or efficacy. In 2014 droxidopa (L-threo-3,4-dihydroxyphenylserine - NORTHERA; Chelsea Therapeutics, Charlotte, NC) was approved by the FDA for treatment of symptomatic NOH based on data collected in conditions of autonomic dysfunction. Droxidopa is a NE precursor that is stored in neuronal and non-neuronal tissue and has been shown to increase standing BP and reduce symptoms of orthostatic intolerance in individuals with symptomatic NOH. We recently reported preliminary evidence of a mean increase in seated BP in individuals with SCI following oral administration of 400 mg of droxidopa; however, this dose was effective in only 5 of the 10 subjects tested and the BP effect waned over a 4-hour observation. Because of its unique pharmacokinetic profile, droxidopa is a highly promising agent to treat hypotension in persons with SCI. As such; there exists a pressing imperative to determine the clinical value and safety of droxidopa in hypotensive individuals with SCI.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 65 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury
Actual Study Start Date : June 1, 2018
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2020


Arm Intervention/treatment
Experimental: Study 1: Dose Optimization of Northera
Subjects will be administered oral droxidopa in a dose escalation, open-label manner beginning with 200 mg. The dose will be adjusted upwards by 100 mg on subsequent visits until average Systolic Blood Pressure (SBP) recorded 60-120 minutes after dose administration is 111-139 mmHg in males and 101-139 mmHg in females, sustained elevation (≥ 30 consecutive minutes) in seated SBP ≥ 140/100 mmHg, maximum dose of 800 mg is reached without adequate SBP response. Subjects will visit the testing laboratory on as few as 1 (200 mg) and as many as 7 (800 mg) days. Seated cardiovascular assessments will be monitored and recorded at 15-minute intervals for 4-hours, and the side effects questionnaire will be administered hourly during the 4-hour study. Each study visit will take about 5 hours.
Drug: Northera
Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg. Study 2 is blinded placebo controlled trial using the individualized optimal dose of droxidopa determined by study 1.
Other Name: Droxidopa

Placebo Comparator: Study 2: Blinded Placebo & Northera
Participants will then be administered either oral optimal dose of Northera (Droxidopa) or matching placebo in a double-blinded manner and will remain in the supine position for 60 minutes. Subjects will remain in their wheelchair for instrumentation, which will include: 1) ECG, 2) brachial BP, 3) finger arteriolar BP and 4) Cerebral Blood Flow velocity (CBFv).
Drug: Northera
Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg. Study 2 is blinded placebo controlled trial using the individualized optimal dose of droxidopa determined by study 1.
Other Name: Droxidopa




Primary Outcome Measures :
  1. Proportion of subjects with normotensive systolic blood pressure [ Time Frame: 60 to 120 minutes following administration of droxidopa ]
    To determine the proportion (%) of hypotensive participants with SCI who have a normotensive systolic blood pressure (males=111-139 mmHg; females=101-139 mmHg) following administration of droxidopa.


Secondary Outcome Measures :
  1. Supine systolic blood pressure [ Time Frame: within 60 minutes of administration of droxidopa or placebo ]
    To measure supine systolic blood pressure following administration of droxidopa compared to placebo in hypotensive participants with SCI

  2. Orthostatic systolic Blood Pressure [ Time Frame: 60-90 minutes following administration of droxidopa or placebo ]
    To document systolic blood pressure responses to head-up tilt to 70 degrees following administration of droxidopa compared to placebo in hypotensive participants with SCI.

  3. Change in cerebral blood flow [ Time Frame: 60-90 minutes following administration of droxidopa or placebo ]
    To document change (from supine to 70 degrees head-up tilt) in cerebral blood flow velocity in the middle cerebral artery following administration of droxidopa compared to placebo in hypotensive participants with SCI.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Study 1:

  1. Male or Female, age 18 to 89 with traumatic SCI.
  2. SCI Subjects (n=40):

    1. Any level of injury;
    2. Any American Spinal Injury Association Impairment Scale (AIS) grade of SCI;
    3. Non-ventilator dependent
    4. Primarily wheelchair dependent for mobility;
    5. Duration of injury < 1 year
  3. Low Blood Pressure:

    1. Systolic BP less than 110 mmHg and/or diastolic BP less than 70 mmHg for males.
    2. Systolic BP less than 100 mmHg and/or diastolic BP less than 70 mmHg for females.
  4. Primary Language is English.
  5. Able to provide informed consent

    Study 2:

  6. Male or Female, age 18 to 89 with traumatic SCI.
  7. SCI Subjects (n=40):

    1. Any level of injury;
    2. Any AIS grade of SCI;
    3. Non-ventilator dependent
    4. Primarily wheelchair dependent for mobility
    5. Duration of injury < 1 year
  8. Low Blood Pressure:

    1. Systolic BP less than 110 mmHg and/or diastolic BP less than 70 mmHg for males.
    2. Systolic BP less than 100 mmHg and/or diastolic BP less than 70 mmHg for females.
  9. Primary Language is English.
  10. Able to provide informed consent
  11. Showed a normotensive blood pressure in response to Droxidopa during study 1.

Exclusion Criteria:

  • Current illness or infection
  • Individuals with frequent or severe autonomic dysreflexia:

    1. More than 3 symptomatic events per week
    2. BP ≥140/90 mmHg
    3. Significant adverse subjective symptoms reporting
  • Hypertension
  • Any neurological condition other than SCI (Alzheimer's disease, dementia, stroke, multiple sclerosis, Parkinson's disease, etc.)
  • History of epilepsy or other seizure disorder
  • History of traumatic brain injury (TBI)
  • Liver or kidney disease
  • Bladder problems including blockage of the urine and/or weak urine stream.
  • Diagnosis of a psychiatric disorder such as schizophrenia or bipolar disorder
  • Known artery disease, heart failure, Atrio-ventricular block, and irregular heartbeat
  • Any allergies to droxidopa, asprin, polyethylene oxide, polyethylene glycol, hydroxypropyl cellulose, butylated hydroxytoluene, magnesium stearate, hypromellose, yellow ferric oxide, and red ferric oxide
  • Major surgery in the last 30 days
  • Illicit drug abuse in the past 6 months
  • Pregnant
  • Your prescription medications will be reviewed by the study investigators and research staff. If you are currently taking medications to treat any of the following please make the investigators aware:

    d. Depression, Schizophrenia, Attention Deficit Hyperactivity Disorder (ADHD) e. Pain (opioids) f. Infection or illness (antibiotics) g. Erectile dysfunction (Viagra, Cialis, etc.) h. Overactive bladder i. High or low blood pressure j. Migraine headaches k. Malaria l. asthma


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03602014


Contacts
Layout table for location contacts
Contact: James M LiMonta, BS 718 584 9000 ext 1732 james.limonta@va.gov
Contact: Matt T Maher, MS 718 584 9000 ext 1706 Matthew.Maher@va.gov

Locations
Layout table for location information
United States, New York
James J. Peters Veteran's Affair Medical Center Recruiting
Bronx, New York, United States, 10468
Contact: Jill M. Wecht, Ed.D    718-584-9000 ext 3122    JM.Wecht@va.gov   
Contact: William Bauman, MD    718-584-9000 ext 5428    William.Bauman@va.gov   
The Icahn School of Medicine at Mount Sinai Recruiting
New York, New York, United States, 10029
Contact: Miguel Escalón, MD, MPH    212-241-6321    miguel.escalon@mountsinai.org   
Sponsors and Collaborators
James J. Peters Veterans Affairs Medical Center
New York State Department of Health
Investigators
Layout table for investigator information
Principal Investigator: Jill M Wecht, Ed.D James J. Peter's VAMC
  Study Documents (Full-Text)

Documents provided by Jill M. Wecht, Ed.D., James J. Peters Veterans Affairs Medical Center:
Study Protocol  [PDF] February 6, 2019


Publications:

Layout table for additonal information
Responsible Party: Jill M. Wecht, Ed.D., Principal Investigator, James J. Peters Veterans Affairs Medical Center
ClinicalTrials.gov Identifier: NCT03602014     History of Changes
Other Study ID Numbers: WEC-17-042
First Posted: July 26, 2018    Key Record Dates
Last Update Posted: August 8, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jill M. Wecht, Ed.D., James J. Peters Veterans Affairs Medical Center:
Hypotension
Spinal Cord Injury
Droxidopa
Northera
Neurogenic Orthostatic Hypotension

Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Cord Injuries
Hypotension, Orthostatic
Hypotension
Wounds and Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Vascular Diseases
Cardiovascular Diseases
Orthostatic Intolerance
Primary Dysautonomias
Autonomic Nervous System Diseases
Norepinephrine
Droxidopa
Antihypertensive Agents
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Antiparkinson Agents
Anti-Dyskinesia Agents